Welcome to our dedicated page for PRECISION BIOSCIENCES SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PRECISION BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PRECISION BIOSCIENCES's regulatory disclosures and financial reporting.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested, each representing one share of common stock, as part of an award scheduled to vest in three equal annual installments beginning on that date.
In connection with this vesting, on February 18, 2026 he executed an open-market sell-to-cover of 4,925 common shares at $3.84 per share under a pre-established Rule 10b5-1 plan, solely to satisfy tax withholding and related fees. After these transactions, he directly held 121,926 common shares and 33,333 RSUs, with an additional 7,931 common shares held indirectly through a charitable remainder unitrust.
DTIL reported Form 144 transactions involving restricted stock vesting and a recent resale. The filing shows 4,925 common shares listed under "Securities To Be Sold" with an event date of 02/17/2026 described as "Restricted Stock Vesting" and labeled "Issuer" and "Compensation". The filing also records that 10,200 common shares were sold by James Jefferson Revocable Trust on 01/21/2026 for $41,073.36.
DTIL reported an insider sale notice for common stock under Form 144. The filing lists 4,925 shares as restricted stock vesting to be sold on 02/17/2026 and shows 8,854 shares sold during the prior three months on 01/21/2026. The broker listed is Fidelity Brokerage Services LLC.
DTIL reported a Form 144 filing in which Michael Amoroso indicated a sale of 34,799 common shares on 01/22/2026 for $145,202.30. The filing also shows 20,559 common shares vested as restricted stock on 02/17/2026 as compensation.
DTIL insider John A. Kelly filed a Form 144 reporting a proposed sale of 8,149 common shares that vested as restricted stock on 02/17/2026, handled through Fidelity Brokerage Services LLC. The filing also discloses a prior sale of 15,213 common shares on 01/21/2026.
Tang Capital Management and related entities report that they no longer own any Precision BioSciences, Inc. common stock. In Amendment No. 3 to their Schedule 13G, they state beneficial ownership of 0 shares, representing 0% of the company’s common stock as of December 31, 2025.
Each reporting person lists zero sole or shared voting power and zero sole or shared dispositive power over Precision BioSciences shares. They also certify that any securities previously held were not acquired or held to change or influence control of the company.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 shares of Precision BioSciences, Inc. common stock, equal to 4.1% of the class as of the calculation date. They hold shared voting and dispositive power over all reported shares, with no sole authority.
The ownership percentage is based on 24,071,751 shares of common stock outstanding, combining 10,815,000 shares issued in a recent offering with 13,256,751 shares outstanding as of October 29, 2025. The reporting persons certify the position is not held to change or influence control of the company.
Bleichroeder LP and related entities have reported a significant ownership position in Precision Biosciences, Inc. They are deemed to beneficially own 1,900,000 common shares, representing 8.21% of the company’s common stock believed to be outstanding as of 12/31/2025.
The shares are held for various advisory clients of Bleichroeder LP, which is a registered investment adviser. Clients have the right to receive dividends and sale proceeds from these securities. The filing states that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Precision Biosciences.
Precision BioSciences received U.S. FDA clearance of an investigational new drug application for PBGENE-DMD, its first-in-class in vivo gene editing therapy for Duchenne muscular dystrophy. This “Study May Proceed” notification allows initiation of site activation for the Phase 1/2 FUNCTION-DMD clinical trial in ambulatory patients.
PBGENE-DMD uses a gene excision approach to permanently correct dystrophin gene mutations between exons 45 and 55, a region affecting about 60% of boys with Duchenne muscular dystrophy. The therapy is designed to restore near full-length dystrophin protein at about 80% of normal size, substantially larger than micro-dystrophin constructs approved or in development.
The company plans to activate the first U.S. clinical site in the first half of 2026 and expects initial data from multiple patients by year end 2026. PBGENE-DMD has Rare Pediatric Disease and Orphan Drug designations, and a virtual investor event is planned in March to discuss the program and trial.
Precision BioSciences, Inc. received a significant ownership disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The reporting group beneficially owns 2,328,485 common shares of Precision BioSciences, equal to 9.99% of the class.
The stake consists of 1,917,995 common shares held directly and 410,490 common shares issuable upon exercise of warrants. These percentages are based on 22,897,665 common shares outstanding as of December 30, 2025, as referenced from a Form S-3. The warrants are subject to a 9.99% beneficial ownership blocker, so they cannot be exercised if doing so would push the group above that threshold.
Voting and dispositive power over all 2,328,485 shares are reported as shared among the reporting persons. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.